Basic Efavirenz Information

• INN (International Nonproprietary Name): Efavirenz
• Brand Names Available In United Kingdom: Stocrin, Atripla, Efavirenz Mylan, Efavirenz Teva, Efavirenz Zentiva; typical forms and dosages include 200mg and 600mg tablets supplied by Teva UK and Mylan.
• ATC Code: J05AG03
• Forms & Dosages: Tablet 600mg and 200mg (blister or bottle); capsule 50mg (paediatric) and 200mg (bottle); combination tablet Atripla contains 600mg efavirenz + 200mg emtricitabine + 300mg tenofovir disoproxil (blister).
• Manufacturers In United Kingdom: Generic players (Teva, Mylan, Zentiva, Sandoz, Accord, others) and originator Bristol-Myers Squibb (BMS) for Stocrin/Sustiva.
• Registration Status In United Kingdom: Approved and registered; efavirenz is authorised and marketed across EU/EEA and the UK with national approvals referenced to MHRA and similar national agencies.
• OTC / Rx Classification: Prescription Only (Rx).

Latest Research Highlights (Uk & Eu Focus)

Patients and clinicians often ask whether efavirenz remains a reasonable option compared with newer agents.

Recent UK and EU literature from 2022–2024 has focused on tolerability, dose optimisation and real‑world safety of efavirenz-containing regimens.

Meta-analyses and cohort studies confirm high virological efficacy when efavirenz is used as part of combination antiretroviral therapy.

Consistently, central nervous system adverse events — insomnia, vivid dreams and mood changes — are the principal tolerability concern with efavirenz.

Pharmacokinetic reviews in European populations note variability related to CYP2B6 polymorphisms that can influence plasma levels and the risk of CNS effects.

Some UK genotyping projects have explored personalised dosing strategies, though routine genotype-guided efavirenz dosing is not universally implemented.

Guideline comparisons across the UK and EU increasingly favour switching to integrase inhibitors such as dolutegravir for superior tolerability.

Despite that, efavirenz remains relevant where fixed-dose combinations such as Atripla are used, or in resource-sensitive pathways.

Regulatory context in Europe supports efavirenz’s long-standing authorisation, with EMA approval history and WHO essential medicines listing underlining established clinical utility.

Given the balance of efficacy and tolerability, UK practice now weighs pharmacogenetics and patient vulnerability to CNS effects when considering efavirenz.

Clinical Effectiveness In The Uk

Clinics frequently ask how efavirenz performs in routine NHS practice compared with newer regimens.

Efavirenz 600mg once daily is associated with reliable virological suppression when combined with two nucleoside reverse transcriptase inhibitors.

NHS audits and cohort reports show strong suppression rates at 24–48 weeks, though discontinuation is higher than with dolutegravir-based regimens largely because of neuropsychiatric and CNS events.

Fixed-dose combinations such as Atripla provide once-daily simplicity that supports adherence for some patients.

Efavirenz remains on many national lists and is available on NHS formularies, prescribed by GPs or HIV specialists and dispensed via NHS electronic prescriptions at community pharmacies or hospital dispensaries.

Baseline checks preferred in NHS clinics include mental-health screening, liver function tests and a comprehensive drug–drug interaction review.

• Checklist For Baseline Monitoring: Mental‑health screen; LFTs; interaction check; contraception counselling where relevant.

Indications & Expanded Uses (Mhra & NhS Practice)

Clinicians want clarity on licensed and off‑label uses.

MHRA-approved indication is treatment of HIV‑1 infection as part of combination antiretroviral therapy; WHO and EMA approvals reflect the same indication.

Historically, efavirenz has also been used within some PEP regimens as part of a 28‑day course, though current UK PEP guidance increasingly prefers other agents.

Off‑label use is uncommon but may occur where access to integrase inhibitors is limited or when fixed‑dose combinations such as Atripla offer adherence benefits.

Specialist HIV clinics may consider efavirenz in resource‑sensitive pathways or when resistance testing supports NNRTI use.

Composition & Brand Landscape (Uk Market)

Patients often ask about brand options, generics and pack sizes.

Efavirenz (INN efavirenz; Latin efavirenzum) is available in 600mg and 200mg tablets and 50mg capsules for paediatric use.

The fixed‑dose Atripla tablet combines 600mg efavirenz with 200mg emtricitabine and 300mg tenofovir disoproxil in a single pill.

UK brands include Stocrin, Atripla and generic efavirenz supplied by Mylan, Teva and Zentiva among others.

Packaging is typically blister packs or bottles supplied through NHS procurement channels and community pharmacy wholesalers; specific availability varies with local contracts.

Private prescriptions and online pharmacies may offer generics at variable prices, while NHS procurement determines local trust and board stock.

Contraindications & Special Precautions (Patient Groups)

Safety questions are common, especially around psychiatric history and pregnancy.

Absolute contraindications include known hypersensitivity to efavirenz or components and severe hepatic impairment.

Avoid co‑administration with certain agents such as voriconazole, elbasvir/grazoprevir, St John’s Wort, some benzodiazepines and ergot derivatives as advised by MHRA guidance.

Special precautions apply to patients with a psychiatric history, seizures or epilepsy because of the risk of CNS adverse events.

Women of child‑bearing potential should be counselled about teratogenic risk and effective contraception should be in place when efavirenz is used.

Elderly patients require close monitoring as pharmacokinetics have not been fully evaluated in this group.

• Absolute Contraindications: Known hypersensitivity; severe hepatic impairment; listed contraindicated co‑medications.
• Lifestyle Precautions: Advise caution with driving or operating machinery during initial weeks and counsel on alcohol moderation.

Dosage Guidelines (NhS-Recommended Regimens)

Common dosing and monitoring queries are straightforward to address.

The standard adult dose is 600mg orally once daily, taken with or after food to improve absorption in line with WHO DDD of 0.6g per day.

Paediatric dosing is weight-based; for example, children of 35kg or greater may receive 600mg once daily while lower weight bands use 200mg or 300mg tablets or 50mg capsules.

Avoid efavirenz in moderate to severe hepatic impairment and use caution in severe renal disease due to limited data.

Routine monitoring includes baseline and periodic liver function tests, mental‑health assessment and early viral load checks at 4–12 weeks followed by standard clinic schedules.

If CNS adverse events occur, clinicians may consider dose reduction strategies that have been investigated historically or switch to an integrase inhibitor, which is common in UK practice.

Interactions Overview (Food, Drink, Mhra Reports)

Drug interactions are central to safe efavirenz use because of CYP metabolism and induction.

Efavirenz is mainly metabolised by CYP2B6 and induces CYP3A4, producing many clinically important interactions.

Co‑administration with contraindicated drugs such as voriconazole or certain benzodiazepines should be avoided as per MHRA guidance.

Advise patients to avoid St John’s Wort because it lowers efavirenz levels through enzyme induction.

Taking efavirenz with food increases absorption, so patients should be advised to take doses consistently with respect to meals to reduce variability.

Alcohol does not directly alter efavirenz pharmacokinetics but can worsen CNS side effects and increase hepatic risk, so moderation is recommended.

MHRA Yellow Card reports most frequently highlight CNS events, psychiatric effects and occasional severe skin reactions; pharmacists should remain alert to emerging signals.

Cultural Perceptions & Patient Habits (Uk Insight)

Patients regularly request peer experiences before starting or switching therapy.

UK patient forums and HIV charity discussion boards report mixed views: many welcome once‑daily dosing and the convenience of fixed‑dose tablets while others cite vivid dreams, mood changes and concerns about stigma.

Face‑to‑face counselling at community pharmacies such as Boots or LloydsPharmacy remains valued for side‑effect management and medicine queries.

NHS 111 and specialist HIV clinic helplines are commonly used for urgent advice, and NHS patient portals support confidential messaging about repeat dispensing.

Online pharmacies and private suppliers are increasingly used for convenience, but many patients still prefer NHS-linked pharmacies for verified advice and support.

Availability & Pricing Patterns (Uk Regional Detail)

Access and cost depend on whether the patient uses NHS or private channels.

Efavirenz is prescription‑only on the NHS with branded and multiple generics available from Teva, Mylan and Zentiva.

Prescription charges differ across the UK: Scotland, Wales and Northern Ireland have differing exemptions compared with England where standard prescription charges apply unless the patient is exempt.

Local NHS formularies and procurement determine which brands are stocked in English trusts versus Scottish Health Boards.

Community pharmacies dispense NHS electronic prescriptions and may hold limited private stocks; online pharmacies supply generics privately at variable prices.

In our online pharmacy, efavirenz is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Comparable Medicines And Prescribing Preferences

Clinicians commonly need a simple decision aid when choosing between efavirenz and alternatives.

Integrase inhibitors such as dolutegravir have largely displaced efavirenz in many NHS pathways because they offer better tolerability and fewer CNS effects.

Other NNRTIs such as rilpivirine or etravirine are reserved for selected resistance profiles or specific clinical situations.

Pros of efavirenz include once‑daily dosing, decades of clinical experience and availability in fixed‑dose tablets like Atripla.

Cons are CNS adverse events, teratogenicity concerns in women of child‑bearing potential and a heavy interaction burden due to enzyme induction.

• Pros: Simplicity of dosing; fixed‑dose combination availability; well‑established efficacy.
• Cons: CNS side effects; interaction potential; pregnancy considerations.

Use resistance testing, pregnancy plans, psychiatric history and concomitant medications to guide regimen selection in primary and secondary care.

Frequently Asked Questions

Will efavirenz affect my mood or sleep?

Yes. Central nervous system effects such as insomnia, vivid dreams and mood changes are common early on; contact your GP or HIV clinic if you experience severe changes.

Can I become pregnant on efavirenz?

Women of child‑bearing potential should use effective contraception while on efavirenz and discuss pregnancy planning with their specialist because alternatives may be preferred.

Can I drink alcohol or take herbal remedies?

Do not take St John’s Wort as it reduces efavirenz levels; alcohol can worsen CNS effects and increases liver risk, so moderation is recommended.

What if I forget a dose?

Take the missed dose as soon as you remember unless it is close to the next scheduled dose; do not double up on doses.

• When To Seek Urgent Care: Severe rash, new confusion or hallucinations, pronounced behavioural change or signs of liver injury (jaundice, vomiting, marked abdominal pain).

Guidelines For Proper Use (Pharmacist & NhS Counselling)

Pharmacist counselling should focus on adherence, interactions and monitoring actions.

Advise once‑daily dosing with consistent food intake and provide baseline and ongoing LFT and mental‑health monitoring as part of community or clinic care.

Review prescription, OTC medicines and herbal products for interactions and use electronic prescribing flags to highlight contraindications and allergy alerts.

Provide written information leaflets and signpost patients to NHS portals, HIV charities and the MHRA Yellow Card system for adverse reaction reporting.

Community pharmacists should document counselling, offer adherence aids (pill boxes, blister packs) and liaise with specialist HIV teams if switching is considered.

1. Stepwise Counselling Checklist: Explain dose and timing; discuss food and alcohol; review interactions; reinforce contraception advice; arrange baseline LFTs and mental‑health check.
2. Escalation Criteria: New or worsening psychiatric symptoms; severe rash; signs of liver dysfunction; suspected overdose or significant drug interactions.

Delivery Across United Kingdom